Press Releases

WEST DES MOINES, Iowa, July 22, 2019 /PRNewswire/ -- Businessolver®, a leader in SaaS-based benefits administration technology, and its charitable arm, the 

SILVER SPRING, Md., July 22, 2019 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is announcing the launch of its first e-cigarette prevention TV ads educating kids about the dangers of e-cigarette use. The FDA also plans to provide new posters for high schools and educational materials for middle schools across the U.S. as part of

ENGLEWOOD, Colo., July 22, 2019 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical te

LUND, Sweden, July 22, 2019 /PRNewswire/ -- A research group in Lund led by Professor Catharina Svanborg discovered in 1995 that a component of human breast milk kills tumor cells without harming mature, healthy cells. Further experiments and studies have shown that the effect is due to the most common prot

NEW YORK, July 22, 2019 /PRNewswire/ -- Tackling one of the most critical times in a patient's care journey, leading healthcare technology company, CipherHealth, is partnering with an incre

BOSTON, July 22, 2019 /PRNewswire/ -- OM1, a leading health outcomes and technology company, today announced it is has been awarded the CAPSTONE - Outcome Measure Harmonization and Data Infrastructure for Patient

CAPE TOWN, South Africa, July 22, 2019 /PRNewswire/ -- CannaTech is proud to announce that South African cannabis market leader, Southern Sky Group, will be a Platinum Sponsor at our upcoming Cape Town Cannabis Summit this November 24-26. Southe

RIDGEFIELD PARK, New Jersey, July 22, 2019 /PRNewswire/ -- Netlims, a global leader in laboratory information systems (LIS), announced that it has completed the implementation of its flagship LabOS product for Excelsior Diagnostics, a specialized genetics lab. Excelsior Diagnostics has chosen LabOS Core Labs and

LOS ANGELES, July 22, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has completed enrollment in its Phase 3 clinical trial evaluating arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS) ahead of

SYDNEY, July 22, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York, NY will investigate the potential use of Kazia's investigational new drug, GDC-0084, in combination with rad